Concorde Asset Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 8.1% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,458 shares of the company’s stock after buying an additional 184 shares during the period. Concorde Asset Management LLC’s holdings in Johnson & Johnson were worth $394,000 as of its most recent SEC filing.
A number of other large investors have also added to or reduced their stakes in the company. Summit Trail Advisors LLC increased its holdings in shares of Johnson & Johnson by 63.9% in the 2nd quarter. Summit Trail Advisors LLC now owns 20,102 shares of the company’s stock worth $3,327,000 after buying an additional 7,836 shares during the last quarter. Monte Financial Group LLC raised its position in Johnson & Johnson by 0.6% during the second quarter. Monte Financial Group LLC now owns 32,034 shares of the company’s stock valued at $5,302,000 after purchasing an additional 196 shares during the period. Mathes Company Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at approximately $3,337,000. Onyx Bridge Wealth Group LLC increased its position in shares of Johnson & Johnson by 90.7% during the 2nd quarter. Onyx Bridge Wealth Group LLC now owns 5,040 shares of the company’s stock valued at $834,000 after purchasing an additional 2,397 shares during the last quarter. Finally, Benchmark Financial Wealth Advisors LLC boosted its stake in Johnson & Johnson by 4.2% during the second quarter. Benchmark Financial Wealth Advisors LLC now owns 1,947 shares of the company’s stock worth $322,000 after buying an additional 78 shares during the period. Institutional investors own 68.40% of the company’s stock.
Johnson & Johnson Stock Up 0.3 %
Shares of NYSE JNJ opened at $156.85 on Monday. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The stock has a market capitalization of $407.65 billion, a PE ratio of 31.75, a price-to-earnings-growth ratio of 3.21 and a beta of 0.55. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The stock’s fifty day simple moving average is $163.10 and its two-hundred day simple moving average is $162.57.
Johnson & Johnson Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.03%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s payout ratio is presently 96.36%.
Insider Activity
In related news, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares in the company, valued at approximately $15,092,484. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, insider William Hait sold 14,698 shares of the business’s stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now owns 87,747 shares in the company, valued at $15,092,484. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Peter Fasolo sold 20,000 shares of the company’s stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the transaction, the vice president now owns 102,696 shares in the company, valued at approximately $17,491,182.72. The disclosure for this sale can be found here. Company insiders own 0.20% of the company’s stock.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on JNJ shares. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $172.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 11th. Atlantic Securities upped their target price on Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. Wells Fargo & Company decreased their price target on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a research note on Thursday, August 31st. Stifel Nicolaus increased their target price on Johnson & Johnson from $165.00 to $175.00 in a research note on Friday, July 21st. Finally, Credit Suisse Group boosted their target price on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a research note on Friday, July 21st. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and an average price target of $171.00.
Read Our Latest Research Report on Johnson & Johnson
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
Featured Stories
- Five stocks we like better than Johnson & Johnson
- How to Read Stock Charts for Beginners
- MarketBeat Week in Review – 10/9 – 10/13
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- What BlackRock’s Earnings Tell You About The Stock Market Tide
- The How and Why of Investing in Gold Stocks
- Sociedad Quimica y Minera de Chile Well Positioned Lithium Stock
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
